These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 8139023)

  • 1. In vivo evolution of c-rel oncogenic potential.
    Hrdlicková R; Nehyba J; Humphries EH
    J Virol; 1994 Apr; 68(4):2371-82. PubMed ID: 8139023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformation.
    Nehyba J; Hrdlicková R; Humphries EH
    J Virol; 1994 Apr; 68(4):2039-50. PubMed ID: 8138989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analysis of v-rel, the oncogene of reticuloendotheliosis virus strain T.
    Bhat GV; Temin HM
    Oncogene; 1990 May; 5(5):625-34. PubMed ID: 2189101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. v-rel induces expression of three avian immunoregulatory surface receptors more efficiently than c-rel.
    Hrdlicková R; Nehyba J; Humphries EH
    J Virol; 1994 Jan; 68(1):308-19. PubMed ID: 8254742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids.
    Kralova J; Schatzle JD; Bargmann W; Bose HR
    J Virol; 1994 Apr; 68(4):2073-83. PubMed ID: 8138992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N-terminal env-derived amino acids of v-rel are required for full transforming activity.
    Garson K; Percival H; Kang CY
    Virology; 1990 Jul; 177(1):106-15. PubMed ID: 2162102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in kappaB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein.
    Nehyba J; Hrdlicková R; Bose HR
    Oncogene; 1997 Jun; 14(24):2881-97. PubMed ID: 9205096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential pp40I kappa B-beta inhibition of DNA binding by rel proteins.
    Diehl JA; McKinsey TA; Hannink M
    Mol Cell Biol; 1993 Mar; 13(3):1769-78. PubMed ID: 8441412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation of avian lymphoid cells by reticuloendotheliosis virus.
    Moore BE; Bose HR
    Mutat Res; 1988 Jan; 195(1):79-90. PubMed ID: 2827014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the DNA-binding and dimerization domains of v-Rel are responsible for altered kappa B DNA-binding complexes in transformed cells.
    Hrdlicková R; Nehyba J; Bose HR
    J Virol; 1995 Jun; 69(6):3369-80. PubMed ID: 7745683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation.
    Walker WH; Stein B; Ganchi PA; Hoffman JA; Kaufman PA; Ballard DW; Hannink M; Greene WC
    J Virol; 1992 Aug; 66(8):5018-29. PubMed ID: 1321284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of oncogenicity of the c-rel proto-oncogene.
    Sylla BS; Temin HM
    Mol Cell Biol; 1986 Dec; 6(12):4709-16. PubMed ID: 3025667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene expression in reticuloendotheliosis virus-transformed lymphoid cell lines and avian tissues.
    Herzog NK; Bargmann WJ; Bose HR
    J Virol; 1986 Jan; 57(1):371-5. PubMed ID: 2867231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
    Mosialos G; Gilmore TD
    Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic transformation by vrel requires an amino-terminal activation domain.
    Kamens J; Richardson P; Mosialos G; Brent R; Gilmore T
    Mol Cell Biol; 1990 Jun; 10(6):2840-7. PubMed ID: 2111443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The v-rel oncogene product is complexed with cellular proteins including its proto-oncogene product and heat shock protein 70.
    Lim MY; Davis N; Zhang JY; Bose HR
    Virology; 1990 Mar; 175(1):149-60. PubMed ID: 2155506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the v-rel oncogene in reticuloendotheliosis virus-transformed fibroblasts.
    Moore BE; Bose HR
    Virology; 1988 Feb; 162(2):377-87. PubMed ID: 2829425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three mutations in v-Rel render it resistant to cleavage by cell-death protease caspase-3.
    Barkett M; Dooher JE; Lemonnier L; Simmons L; Scarpati JN; Wang Y; Gilmore TD
    Biochim Biophys Acta; 2001 Apr; 1526(1):25-36. PubMed ID: 11287119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
    Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
    Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Rel family: models for transcriptional regulation and oncogenic transformation.
    Bose HR
    Biochim Biophys Acta; 1992 Sep; 1114(1):1-17. PubMed ID: 1327144
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.